Your browser has either disabled or does not support javascript. Javascript is required for full website experience.
BiondVax Pharmaceuticals Ltd. ADR
BVXV
$
2.9
-10%
Fri October 23rd, 2020
21:03
Analysis
Why BiondVax Pharmaceuticals Stock Imploded Today
The Motley Fool
14:38
Press Releases
BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate
PR Newswire
Fri October 2nd, 2020
10:00
Press Releases
BiondVax Announces At-The-Market (ATM) Equity Offering Program
PR Newswire
Tue September 1st, 2020
22:21
Analysis
BiondVax Pharmaceuticals: A Small, Undervalued Biotech Company
Seeking Alpha
Thu August 20th, 2020
20:01
Press Releases
BiondVax Announces Second Quarter 2020 Financial Results
PR Newswire
Wed July 1st, 2020
10:00
Press Releases
Last of 12,400 Participants Completes Final Visit in BiondVax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
PR Newswire
Tue June 30th, 2020
20:01
Press Releases
BiondVax Announces First Quarter 2020 Financial Results
PR Newswire
Fri June 12th, 2020
12:00
Press Releases
BiondVax Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
PR Newswire
Wed June 10th, 2020
11:00
Press Releases
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
PR Newswire
Wed May 20th, 2020
10:30
Press Releases
BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants
PR Newswire
